Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
Lilly pulls out of CNS portion of $960M collab with Rigel
Eli Lilly has pulled out of the CNS portion of a $960 million biobucks deal centered on Rigel’s RIPK1 inhibitors.
James Waldron
Nov 5, 2025 7:00am
Lilly inks $345M antibody pact with XtalPi subsidiary
Nov 5, 2025 7:00am
Eli Lilly sidelines pain prospect in another pipeline shift
Oct 30, 2025 2:19pm
Lilly, Nvidia team up to build industry-leading supercomputer
Oct 28, 2025 3:26pm
Lilly buys cash-strapped Adverum for eye disease gene therapy
Oct 24, 2025 9:25am
Lilly oncology head weighs in on FDA cancer drug policies
Oct 21, 2025 11:53am
